AI Drug Discovery Infrastructure Market to Add US$16.88 Billion by 2032 as Pharma, Cloud and Bio-AI Platforms Rebuild R&D Around Compute, Data and Generative Molecular Design

NEW YORK, May 13, 2026 - The global AI Drug Discovery Infrastructure Market was valued at US$3.10 billion in 2025 and is projected to reach US$19.98 billion by 2032, expanding at a CAGR of 30.5% during 2026-2032, according to Global Reports Store. The forecast represents an additional US$16.88 billion in annual market value by 2032, driven by a deeper structural shift in pharmaceutical research: drug discovery is becoming a compute-intensive, data-led, model-supported operating system rather than a sequence of isolated wet-lab experiments.

Request For Exclusive Sample: https://www.globalreportsstore.com/request-sample/1266/

The strongest market signal is not simply that pharmaceutical companies are "using AI." The more important change is that large drug developers, biotechnology companies, CROs, cloud providers, genome-data platforms and AI-native discovery firms are investing in the infrastructure layer beneath AI-enabled R&D. This includes AI software platforms, high-performance computing, cloud infrastructure, data infrastructure, machine learning operations, automated laboratories, foundation models for biology and chemistry, graph neural networks, generative molecular design and clinical-trial simulation tools.

Traditional drug discovery has long been constrained by high cost, long timelines, low probability of success and incomplete biological understanding. Global Reports Store notes that traditional development can take more than 10 years for a single drug candidate and that AI infrastructure helps reduce early discovery burden by enabling large-scale virtual screening and predictive modeling before laboratory validation. This is where the market is shifting from experimental AI tools to enterprise R&D infrastructure.

For CEOs, CTOs, VPs, product managers and R&D leaders, the strategic question is no longer whether AI can support drug discovery. The question is whether their organization has the data architecture, compute environment, model governance, lab integration and domain workflows to make AI useful at scale. That is why the market is attracting both pharmaceutical buyers and technology infrastructure providers.

Top 5 Key Developments in the Last Six Months: USA and Japan Focus

1. NVIDIA and Lilly committed up to US$1 billion to AI drug discovery infrastructure.
In January 2026, NVIDIA and Eli Lilly announced a co-innovation AI lab in the San Francisco Bay Area, with the companies planning to invest up to US$1 billion over five years in talent, infrastructure and compute. The lab will use NVIDIA BioNeMo and NVIDIA Vera Rubin architecture, with a focus on connecting agentic wet labs and computational dry labs into a continuous learning system. This is one of the clearest examples of the market moving from software licensing to physical and computational infrastructure for 24/7 AI-assisted experimentation.

2. Illumina introduced the Billion Cell Atlas to train AI models at biological scale.
In January 2026, Illumina introduced the Billion Cell Atlas, described as the first tranche of a broader program to build a 5 billion cell atlas over three years. The dataset is being built to support drug target validation and AI model training across the pharmaceutical ecosystem, with AstraZeneca, Merck and Lilly participating as founding alliance members. Illumina said the Atlas will capture how 1 billion individual cells respond to genetic changes via CRISPR across more than 200 disease-relevant cell lines and generate data at a rate of 20 petabytes of single-cell transcriptomic data within a year.

3. Takeda and Iambic created a Japan-linked AI drug discovery deal worth more than US$1.7 billion in potential payments.
In February 2026, Iambic announced a multi-year collaboration with Takeda to apply AI-driven discovery models to small-molecule programs in oncology and gastrointestinal and inflammation areas. Iambic said it will receive upfront, research cost and technology access payments and may receive success-based payments exceeding US$1.7 billion, along with royalties. The agreement also gives Takeda access to NeuralPLexer, Iambic's protein-ligand complex prediction model. For Japan, this is a major signal because Takeda is using external AI infrastructure to de-risk candidate selection and accelerate programs from early project start toward IND.

4. Merck and Mayo Clinic launched a multimodal AI collaboration for precision medicine and drug discovery.
In March 2026, Merck and Mayo Clinic announced an R&D collaboration focused on AI-enabled drug discovery and precision medicine, initially targeting inflammatory bowel disease, atopic dermatitis and multiple sclerosis. The collaboration builds on Merck's AI and machine learning investments across computational biology, spatial biology, foundation models and real-world data. This development highlights a quiet but powerful infrastructure trend: the most valuable AI drug discovery systems will not rely only on chemical libraries, but on clinical, genomic, spatial and multimodal datasets that connect disease biology to patient reality.

5. AWS and Flagship Pioneering moved cloud infrastructure closer to startup-scale life-science company creation.
In April 2026, AWS and Flagship Pioneering announced a strategic collaboration to help Flagship's early-stage companies access AWS cloud credits, technical support, AI services and go-to-market resources. AWS positioned the partnership around secure, scalable infrastructure for rapid experimentation and scaling of drug discovery and scientific platforms. This matters because the next generation of AI drug discovery companies will need enterprise-grade compute and data architecture from the start, rather than adding it after the science matures.

Market Segmentation: Where the Revenue Is Concentrating

By infrastructure component, AI software platforms are the dominant segment. Global Reports Store estimates that software platforms generated US$2.05 billion in 2025, representing 66.1% of total market revenue. The segment is projected to reach US$12.82 billion by 2032, maintaining the largest position in the market. These platforms include molecular simulation software, generative AI drug design systems, predictive analytics tools and target identification algorithms.

This segment is attractive because software is where pharmaceutical workflows are being redesigned. Generative AI is now being used to explore chemical space, propose novel molecules, optimize therapeutic properties and reduce the number of poor candidates entering expensive experiments. However, the real advantage comes when software platforms are connected to proprietary biological data, automated wet labs and model-validation workflows. Companies that only offer a model may struggle; companies that help R&D teams move from target insight to experimental validation will win higher-value contracts.

Computing infrastructure accounted for US$0.72 billion in 2025, equal to 23.2% of the global market, and is projected to reach US$4.64 billion by 2032. This segment includes high-performance computing clusters, GPU-accelerated servers and cloud-based AI training platforms used for molecular modeling, protein interaction analysis and large-scale simulation.

The computing segment is gaining urgency because drug discovery AI is no longer limited to small prediction models. Foundation models for biology and chemistry require large-scale training environments, secure cloud deployment, specialized accelerators and continuous access to high-quality data. For CTOs and infrastructure leaders, the challenge is cost discipline. Compute must be scalable, but it also has to be governed, validated and integrated with scientific workflows.

Data infrastructure generated US$0.33 billion in 2025, representing 10.7% of the market, and is projected to reach US$2.52 billion by 2032. This segment includes biomedical databases, genomic data platforms and chemical compound libraries used to train AI algorithms.

This may be the most underestimated segment. AI drug discovery infrastructure is only as strong as the data feeding it. Poorly labeled assays, fragmented omics data, inconsistent metadata and disconnected clinical records can weaken even the most advanced model. The commercial opportunity is rising for companies that can normalize biomedical data, manage multi-omics pipelines, support secure collaboration and create reusable data products for model training.

The market is further segmented by technology into machine learning, deep learning, natural language processing, generative AI for molecular design, quantum machine learning and graph neural networks. By deployment model, it includes cloud-based infrastructure, on-premise infrastructure and hybrid deployment. By application, the market covers target identification and validation, de-novo drug design, lead identification and optimization, drug repurposing, predictive toxicology and safety modeling, and clinical trial design and simulation. By end user, demand is led by pharmaceutical companies, biotechnology companies, CROs, academic and research institutes, and government and public health organizations.

Regional Analysis:

North America generated US$1.48 billion in revenue in 2025, accounting for 47.7% of the global AI drug discovery infrastructure market. The United States is the commercial center of this regional lead because it brings together large pharmaceutical R&D budgets, AI chip infrastructure, cloud platforms, venture-backed TechBio companies, academic medical centers and regulatory experience with computational evidence.

What is changing in the U.S. is the sales model. AI drug discovery infrastructure is no longer being sold only to innovation teams. It is increasingly being evaluated by R&D leadership, digital transformation teams, translational science groups, data governance leaders and CFOs. Buyers want platforms that can reduce cycle time, improve target confidence, lower avoidable wet-lab work, increase reproducibility and support portfolio decisions. The NVIDIA-Lilly, Illumina, Merck-Mayo and AWS-Flagship developments show the U.S. market moving toward infrastructure partnerships rather than isolated AI pilots.

Japan's opportunity sits inside the broader Asia-Pacific market, which generated US$0.56 billion in 2025, representing 18.1% of global revenue. The region is expected to experience the fastest growth as pharmaceutical companies expand digital research infrastructure across China, Japan and South Korea.

Japan's position is distinctive. It has large pharmaceutical companies, strong academic medical centers, robotics expertise, aging-population pressure, and a need to improve drug discovery productivity. Astellas has already described its internal "human-in-the-loop" AI drug discovery platform, which combines researchers, AI and robotics. The company said the platform is now widely used in low- and middle-molecule drug discovery across its R&D organization, after more than two years of user feedback and refinement.

The Takeda-Iambic deal adds another layer to Japan's market story. Japanese pharma is not simply building everything internally; it is selectively partnering with AI-native platforms to access predictive models, automated lab capabilities and faster design-make-test-analyze cycles. For vendors targeting Japan, credibility will depend on scientific validation, data security, integration with Japanese R&D workflows, and the ability to support researchers rather than replace their judgment.

Competitive Ecosystem

Global Reports Store identifies key participants across three major groups: core AI drug discovery platform companies, AI and technology infrastructure providers, and life science data platform providers. Companies listed in the competitive landscape include Insilico Medicine, Exscientia, Recursion Pharmaceuticals, BenevolentAI, Atomwise, Schrödinger, Valo Health, CytoReason, AbCellera Biologics, NVIDIA, Microsoft, Google DeepMind, Google Cloud, AWS, IBM, Intel, Illumina, IQVIA, Tempus Labs, DNAnexus and Benchling.

The market is not moving toward a single winner. It is forming a layered ecosystem. AI-native biotech companies need infrastructure providers. Pharma companies need software platforms and validated data pipelines. Cloud providers need domain-specific life-science partners. CROs need tools that can translate computational insight into experimental execution. Data companies need to make biological datasets AI-ready. The commercial winners will be the companies that can connect these layers without creating another silo.

Purchase This Exclusive Report: https://www.globalreportsstore.com/checkout/1266/

Analyst View

Global Reports Store believes the AI Drug Discovery Infrastructure Market is entering a more disciplined phase. The early story was speed. The next story is scientific reliability at scale. Decision-makers are asking whether AI systems can produce candidates that survive experimental validation, whether models are trained on relevant biological data, whether workflows are auditable, and whether infrastructure can support regulated pharmaceutical development.

The strongest lead-generation angle for this market is not "AI will discover drugs faster." A sharper message is: AI infrastructure can help pharmaceutical companies turn fragmented biological data, compute, lab automation and molecular design into a repeatable discovery engine. That is the message that will resonate with CEOs, CTOs, VPs, R&D heads, product leaders and strategic buyers in the United States and Japan.

The projected rise from US$3.10 billion in 2025 to US$19.98 billion by 2032 should be viewed as a shift in pharmaceutical operating models. AI drug discovery is no longer only a software category. It is becoming a complete infrastructure stack: data, compute, models, lab integration, validation, deployment and governance. Companies that treat it as a long-term R&D backbone, rather than a short-term productivity tool, will be best positioned to capture value.

Media Contact
Global Reports Store
Office No. 301, Sairam IT Park, Hadapsar, Pune 411028
Email: sales@globalreportsstore.com
Phone: +91 8143002442

About Global Report Store

Global Report Store provides structured market intelligence, revenue analysis, competitive benchmarking, and strategic industry research for organizations evaluating growth opportunities across chemicals, materials, packaging, industrial technology, energy, healthcare, infrastructure, electronics, and specialty manufacturing markets. The Printing Inks Market Trends, Packaging Demand Growth Report is developed to help growth-focused organizations understand market size, ink-type demand, printing-process trends, application growth, regional opportunity, company positioning, regulatory influence, and commercial potential across the global printing inks ecosystem.

This release was published on openPR.